AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. PMNT
  4. [Form 4] Perfect Moment Ltd. Insider Trading Activity

[Form 4] Perfect Moment Ltd. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Cingulate Inc. (CING) filed a Form 4 reporting two stock-option grants to Raul R. Silva, EVP & Chief Scientific Officer.

  • Grant 1: 1,000 options to buy common stock at an exercise price of $4.30 per share. Grant and first exercisable date: 03/31/2025; expiration: 03/31/2035.
  • Grant 2: 1,000 options at an exercise price of $4.07 per share. Grant and first exercisable date: 06/30/2025; expiration: 06/30/2035.

Both grants were made pursuant to Dr. Silva鈥檚 employment agreement and are held directly. No open-market purchases or sales of common stock were reported, and Table I shows no changes in non-derivative holdings. Post-transaction, Dr. Silva beneficially owns 1,000 derivative securities in each grant line, representing incentive alignment but a modest absolute share count.

Cingulate Inc. (CING) ha presentato un Modulo 4 segnalando due assegnazioni di opzioni su azioni a Raul R. Silva, EVP e Chief Scientific Officer.

  • Assegnazione 1: 1.000 opzioni per acquistare azioni ordinarie a un prezzo di esercizio di $4,30 per azione. Data di assegnazione e prima data esercitabile: 31/03/2025; scadenza: 31/03/2035.
  • Assegnazione 2: 1.000 opzioni a un prezzo di esercizio di $4,07 per azione. Data di assegnazione e prima data esercitabile: 30/06/2025; scadenza: 30/06/2035.

Entrambe le assegnazioni sono state effettuate in base al contratto di lavoro del Dott. Silva e sono detenute direttamente. Non sono stati riportati acquisti o vendite di azioni ordinarie sul mercato aperto, e la Tabella I non mostra variazioni nelle partecipazioni non derivate. Dopo la transazione, il Dott. Silva possiede beneficiariamente 1.000 titoli derivati per ciascuna linea di assegnazione, rappresentando un allineamento degli incentivi ma un numero assoluto di azioni modesto.

Cingulate Inc. (CING) present贸 un Formulario 4 reportando dos concesiones de opciones sobre acciones a Raul R. Silva, EVP y Director Cient铆fico.

  • Concesi贸n 1: 1,000 opciones para comprar acciones comunes a un precio de ejercicio de $4.30 por acci贸n. Fecha de concesi贸n y primera fecha ejercitable: 31/03/2025; vencimiento: 31/03/2035.
  • Concesi贸n 2: 1,000 opciones a un precio de ejercicio de $4.07 por acci贸n. Fecha de concesi贸n y primera fecha ejercitable: 30/06/2025; vencimiento: 30/06/2035.

Ambas concesiones se realizaron conforme al contrato laboral del Dr. Silva y se mantienen directamente. No se reportaron compras o ventas en el mercado abierto de acciones comunes, y la Tabla I no muestra cambios en las tenencias no derivadas. Tras la transacci贸n, el Dr. Silva posee beneficiosamente 1,000 valores derivados en cada l铆nea de concesi贸n, lo que representa una alineaci贸n de incentivos pero un recuento absoluto de acciones modesto.

Cingulate Inc. (CING)电� Raul R. Silva, EVP 氚� 斓滉碃 瓿柬暀 毂呾瀯鞛�鞐愱矊 霊� 瓯挫潣 欤检嫕 鞓奠厴 攵�鞐ゼ 氤搓碃頃樀鐢 Form 4毳� 鞝滌稖頄堨姷雼堧嫟.

  • 攵�鞐� 1: 欤茧嫻 頄夓偓 臧�瓴� $4.30鞐� 氤错喌欤� 1,000欤� 鞓奠厴. 攵�鞐� 氚� 斓滌磮 頄夓偓 臧�電レ澕: 2025雲� 3鞗� 31鞚�; 毵岆鞚�: 2035雲� 3鞗� 31鞚�.
  • 攵�鞐� 2: 欤茧嫻 頄夓偓 臧�瓴� $4.07鞐� 1,000 鞓奠厴. 攵�鞐� 氚� 斓滌磮 頄夓偓 臧�電レ澕: 2025雲� 6鞗� 30鞚�; 毵岆鞚�: 2035雲� 6鞗� 30鞚�.

霊� 攵�鞐� 氇憪 Silva 氚曥偓鞚� 瓿犾毄 瓿勳暯鞐� 霐半澕 鞚措（鞏挫鞙茧┌ 歆侅为 氤挫湢 欷戩瀰雼堧嫟. 瓿店皽 鞁滌灔鞐愳劀鞚� 氤错喌欤� 毵るГ电� 氤搓碃霅橃 鞎婌晿鞙茧┌, 響� I鞐惖鐢 牍勴寣靸� 氤挫湢 雮挫棴鞐� 氤�頇旉皜 鞐嗢姷雼堧嫟. 瓯半灅 頉� Silva 氚曥偓电� 臧� 攵�鞐� 霛检澑氤勲 1,000臧滌潣 韺岇儩 歃濌秾鞚� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚吹鐢 鞚胳劶韹半笇 鞝曤牞鞚� 雮橅儉雮挫毵� 鞝堧寑 欤检嫕 靾樀鐢 鞝侅潃 韼胳瀰雼堧嫟.

Cingulate Inc. (CING) a d茅pos茅 un formulaire 4 signalant deux attributions d鈥檕ptions d鈥檃chat d鈥檃ctions 脿 Raul R. Silva, EVP et Directeur scientifique.

  • Attribution 1 : 1 000 options d鈥檃chat d鈥檃ctions ordinaires 脿 un prix d鈥檈xercice de 4,30 $ par action. Date d鈥檃ttribution et premi猫re date d鈥檈xercice : 31/03/2025 ; expiration : 31/03/2035.
  • Attribution 2 : 1 000 options 脿 un prix d鈥檈xercice de 4,07 $ par action. Date d鈥檃ttribution et premi猫re date d鈥檈xercice : 30/06/2025 ; expiration : 30/06/2035.

Les deux attributions ont 茅t茅 effectu茅es conform茅ment au contrat de travail du Dr Silva et sont d茅tenues directement. Aucun achat ou vente d鈥檃ctions ordinaires sur le march茅 ouvert n鈥檃 茅t茅 signal茅, et le tableau I ne montre aucun changement dans les d茅tentions non d茅riv茅es. Apr猫s la transaction, le Dr Silva d茅tient b茅n茅ficiairement 1 000 titres d茅riv茅s pour chaque attribution, ce qui refl猫te un alignement des incitations mais un nombre absolu d鈥檃ctions modeste.

Cingulate Inc. (CING) hat ein Formular 4 eingereicht, in dem zwei Aktienoptionszuteilungen an Raul R. Silva, EVP und Chief Scientific Officer, gemeldet werden.

  • Zuteilung 1: 1.000 Optionen zum Kauf von Stammaktien zu einem Aus眉bungspreis von $4,30 pro Aktie. Zuteilungs- und erstes Aus眉bungsdatum: 31.03.2025; Ablaufdatum: 31.03.2035.
  • Zuteilung 2: 1.000 Optionen zu einem Aus眉bungspreis von $4,07 pro Aktie. Zuteilungs- und erstes Aus眉bungsdatum: 30.06.2025; Ablaufdatum: 30.06.2035.

Beide Zuteilungen erfolgten gem盲脽 Dr. Silvas Arbeitsvertrag und werden direkt gehalten. Es wurden keine K盲ufe oder Verk盲ufe von Stammaktien am offenen Markt gemeldet, und Tabelle I zeigt keine 脛nderungen bei den nicht-derivativen Best盲nden. Nach der Transaktion besitzt Dr. Silva wirtschaftlich jeweils 1.000 derivative Wertpapiere pro Zuteilung, was eine Anreizangleichung darstellt, jedoch eine moderate absolute Aktienanzahl.

Positive
  • None.
Negative
  • None.

Insights

TL;DR Small option grants to an officer; routine incentive alignment, limited market impact.

The reported grants total 2,000 options with 10-year lives and strike prices in the low-$4 range, roughly aligning with typical at-the-money compensation awards for emerging biopharma executives. Because no common shares were bought or sold for cash, there is no immediate liquidity signal. The size is immaterial relative to most public floats, so market impact should be negligible. Nonetheless, the issuance extends retention incentives and ties compensation to long-term shareholder value.

Cingulate Inc. (CING) ha presentato un Modulo 4 segnalando due assegnazioni di opzioni su azioni a Raul R. Silva, EVP e Chief Scientific Officer.

  • Assegnazione 1: 1.000 opzioni per acquistare azioni ordinarie a un prezzo di esercizio di $4,30 per azione. Data di assegnazione e prima data esercitabile: 31/03/2025; scadenza: 31/03/2035.
  • Assegnazione 2: 1.000 opzioni a un prezzo di esercizio di $4,07 per azione. Data di assegnazione e prima data esercitabile: 30/06/2025; scadenza: 30/06/2035.

Entrambe le assegnazioni sono state effettuate in base al contratto di lavoro del Dott. Silva e sono detenute direttamente. Non sono stati riportati acquisti o vendite di azioni ordinarie sul mercato aperto, e la Tabella I non mostra variazioni nelle partecipazioni non derivate. Dopo la transazione, il Dott. Silva possiede beneficiariamente 1.000 titoli derivati per ciascuna linea di assegnazione, rappresentando un allineamento degli incentivi ma un numero assoluto di azioni modesto.

Cingulate Inc. (CING) present贸 un Formulario 4 reportando dos concesiones de opciones sobre acciones a Raul R. Silva, EVP y Director Cient铆fico.

  • Concesi贸n 1: 1,000 opciones para comprar acciones comunes a un precio de ejercicio de $4.30 por acci贸n. Fecha de concesi贸n y primera fecha ejercitable: 31/03/2025; vencimiento: 31/03/2035.
  • Concesi贸n 2: 1,000 opciones a un precio de ejercicio de $4.07 por acci贸n. Fecha de concesi贸n y primera fecha ejercitable: 30/06/2025; vencimiento: 30/06/2035.

Ambas concesiones se realizaron conforme al contrato laboral del Dr. Silva y se mantienen directamente. No se reportaron compras o ventas en el mercado abierto de acciones comunes, y la Tabla I no muestra cambios en las tenencias no derivadas. Tras la transacci贸n, el Dr. Silva posee beneficiosamente 1,000 valores derivados en cada l铆nea de concesi贸n, lo que representa una alineaci贸n de incentivos pero un recuento absoluto de acciones modesto.

Cingulate Inc. (CING)电� Raul R. Silva, EVP 氚� 斓滉碃 瓿柬暀 毂呾瀯鞛�鞐愱矊 霊� 瓯挫潣 欤检嫕 鞓奠厴 攵�鞐ゼ 氤搓碃頃樀鐢 Form 4毳� 鞝滌稖頄堨姷雼堧嫟.

  • 攵�鞐� 1: 欤茧嫻 頄夓偓 臧�瓴� $4.30鞐� 氤错喌欤� 1,000欤� 鞓奠厴. 攵�鞐� 氚� 斓滌磮 頄夓偓 臧�電レ澕: 2025雲� 3鞗� 31鞚�; 毵岆鞚�: 2035雲� 3鞗� 31鞚�.
  • 攵�鞐� 2: 欤茧嫻 頄夓偓 臧�瓴� $4.07鞐� 1,000 鞓奠厴. 攵�鞐� 氚� 斓滌磮 頄夓偓 臧�電レ澕: 2025雲� 6鞗� 30鞚�; 毵岆鞚�: 2035雲� 6鞗� 30鞚�.

霊� 攵�鞐� 氇憪 Silva 氚曥偓鞚� 瓿犾毄 瓿勳暯鞐� 霐半澕 鞚措（鞏挫鞙茧┌ 歆侅为 氤挫湢 欷戩瀰雼堧嫟. 瓿店皽 鞁滌灔鞐愳劀鞚� 氤错喌欤� 毵るГ电� 氤搓碃霅橃 鞎婌晿鞙茧┌, 響� I鞐惖鐢 牍勴寣靸� 氤挫湢 雮挫棴鞐� 氤�頇旉皜 鞐嗢姷雼堧嫟. 瓯半灅 頉� Silva 氚曥偓电� 臧� 攵�鞐� 霛检澑氤勲 1,000臧滌潣 韺岇儩 歃濌秾鞚� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚吹鐢 鞚胳劶韹半笇 鞝曤牞鞚� 雮橅儉雮挫毵� 鞝堧寑 欤检嫕 靾樀鐢 鞝侅潃 韼胳瀰雼堧嫟.

Cingulate Inc. (CING) a d茅pos茅 un formulaire 4 signalant deux attributions d鈥檕ptions d鈥檃chat d鈥檃ctions 脿 Raul R. Silva, EVP et Directeur scientifique.

  • Attribution 1 : 1 000 options d鈥檃chat d鈥檃ctions ordinaires 脿 un prix d鈥檈xercice de 4,30 $ par action. Date d鈥檃ttribution et premi猫re date d鈥檈xercice : 31/03/2025 ; expiration : 31/03/2035.
  • Attribution 2 : 1 000 options 脿 un prix d鈥檈xercice de 4,07 $ par action. Date d鈥檃ttribution et premi猫re date d鈥檈xercice : 30/06/2025 ; expiration : 30/06/2035.

Les deux attributions ont 茅t茅 effectu茅es conform茅ment au contrat de travail du Dr Silva et sont d茅tenues directement. Aucun achat ou vente d鈥檃ctions ordinaires sur le march茅 ouvert n鈥檃 茅t茅 signal茅, et le tableau I ne montre aucun changement dans les d茅tentions non d茅riv茅es. Apr猫s la transaction, le Dr Silva d茅tient b茅n茅ficiairement 1 000 titres d茅riv茅s pour chaque attribution, ce qui refl猫te un alignement des incitations mais un nombre absolu d鈥檃ctions modeste.

Cingulate Inc. (CING) hat ein Formular 4 eingereicht, in dem zwei Aktienoptionszuteilungen an Raul R. Silva, EVP und Chief Scientific Officer, gemeldet werden.

  • Zuteilung 1: 1.000 Optionen zum Kauf von Stammaktien zu einem Aus眉bungspreis von $4,30 pro Aktie. Zuteilungs- und erstes Aus眉bungsdatum: 31.03.2025; Ablaufdatum: 31.03.2035.
  • Zuteilung 2: 1.000 Optionen zu einem Aus眉bungspreis von $4,07 pro Aktie. Zuteilungs- und erstes Aus眉bungsdatum: 30.06.2025; Ablaufdatum: 30.06.2035.

Beide Zuteilungen erfolgten gem盲脽 Dr. Silvas Arbeitsvertrag und werden direkt gehalten. Es wurden keine K盲ufe oder Verk盲ufe von Stammaktien am offenen Markt gemeldet, und Tabelle I zeigt keine 脛nderungen bei den nicht-derivativen Best盲nden. Nach der Transaktion besitzt Dr. Silva wirtschaftlich jeweils 1.000 derivative Wertpapiere pro Zuteilung, was eine Anreizangleichung darstellt, jedoch eine moderate absolute Aktienanzahl.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gottschalk Max
(Last) (First) (Middle)
244 5TH AVENUE
SUITE 1219
(Street)
NEW YORK NY 10001
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Perfect Moment Ltd. [ PMNT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 P 1,692,694(1) A $0.3 2,024,447 I By Joachim Gottschalk & Associates Ltd.(2)
Common Stock 47,020 D
Common Stock 316,600 I By Reporting Person's Spouse(3)
Common Stock 3,479,491 I By Fermain Limited(4)
Series AA Preferred Stock 344,797 I By Joachim Gottschalk & Associates Ltd.(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Issuer entered into a Securities Purchase Agreement (the "Agreement") with Joachim Gottschalk & Associates ("JGA"). Further to the Agreement, JGA, converted all principal and unpaid interest owing further to a promissory note evidencing a $500,000 loan previously made by JGA to the Issuer into 1,692,694 shares of common stock at a per share conversion rate of $0.30. See also footnote 2.
2. The Gottschalk Family Trust is the 100% owner of Joachim Gottschalk & Associates Ltd. and Credit Suisse Trust Limited is the Trustee of the Gottschalk Family Trust. Credit Suisse Trust Limited takes direction from the Reporting Person's Spouse, as a beneficiary of the Gottschalk Family Trust. The Reporting Person disclaims beneficial ownership of the shares reported herein except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission that the Reporting Person is a beneficial owner of the securities reported in this filing for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
3. Shares owned by Reporting Person's spouse Jane Gottschalk. Reporting Person and his spouse each share voting and dispositive control over the shares of common stock beneficially owned by the other.
4. Fermain Limited ("Fermain") is controlled by Reporting Person and his spouse, Jane Gottschalk, each of whom shares voting and dispositive control over Fermain's shares with no single person controlling investment or voting decisions with respect to such shares. Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any. Inclusion of shares owned by Fermain shall not be deemed an admission that the Reporting Person is a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended..
Remarks:
/s/ Max Gottschalk 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did CING insider Raul R. Silva report on the Form 4?

He received two stock-option grants totaling 2,000 options with strikes of $4.30 and $4.07 per share.

Were any Cingulate Inc. common shares bought or sold by the insider?

No. The filing shows no acquisitions or disposals of non-derivative common stock.

What are the exercise and expiration dates of the options?

Grant 1: exercisable 03/31/2025, expires 03/31/2035. Grant 2: exercisable 06/30/2025, expires 06/30/2035.

How many derivative securities does Dr. Silva own after these grants?

The filing lists 1,000 options under each grant line, held directly.

Does the filing indicate a 10b5-1 trading plan?

The form includes the new Rule 10b5-1(c) checkbox, but it is not marked as selected.
Stock PMNT logo
PERFECT MOMENT LTD

NYSE:PMNT

PMNT Rankings

#8737 Ranked by Market Cap
N/A Ranked by Dividends

PMNT Latest News

Jul 7, 2025
Perfect Moment Opens New European Distribution Hub in the Netherlands as Part of Global Logistics Transformation
Jun 30, 2025
Perfect Moment Ltd. Announces Closing of Public Offering
Jun 26, 2025
Perfect Moment Ltd. Announces Pricing of Public Offering
Jun 26, 2025
Perfect Moment Ltd. Announces Proposed Public Offering of Common Stock
Jun 25, 2025
Perfect Moment and BWT Alpine Formula One Team Launch Limited-Edition Luxury Performance Collection

PMNT Latest SEC Filings

Jul 23, 2025
[8-K] Perfect Moment Ltd. Reports Material Event
Jul 11, 2025
[Form 4] Perfect Moment Ltd. Insider Trading Activity
Jul 7, 2025
[8-K] Perfect Moment Ltd. Reports Material Event
Jul 2, 2025
[Form 4] Perfect Moment Ltd. Insider Trading Activity
Jul 2, 2025
[SCHEDULE 13G] Perfect Moment Ltd. SEC Filing

PMNT Stock Data

9.64M
23.28M
37.85%
1.89%
0.88%
Apparel Manufacturing
Apparel & Other Finishd Prods of Fabrics & Similar Matl
United Kingdom
NEW YORK